Drug intelligence / Profile preview

Shaobei injection

Development stage: Preclinical
Modality: Classical Binding Small Molecules → Small Molecules
Administration: Local Injection

Overview

Shaobei injection is a traditional Chinese medicine extract used as a sclerosing agent for the minimally invasive treatment of grade II–III internal hemorrhoids. It is administered via local injection and has been shown in clinical studies to be effective and safe, with fewer adverse effects compared to other sclerosing agents such as Xiaozhiling Injection. The mechanism of action may involve modulation of fibulin protein family members (fibulin-3 and fibulin-5), which are associated with tissue repair and fibrosis. The drug is considered an alternative to conventional sclerotherapy agents in hemorrhoid management[1][2][4].

Brand names: Shaobei injectionAn's Shaobei Injection
Other names: 安氏芍倍注射液 (An's Shaobei Injection)

Targets

FBLN5

Beyond the preview

Go deeper on Shaobei injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shaobei injection.

Explore the full profile